144 related articles for article (PubMed ID: 26794829)
1. Animal Models of Light Chain Deposition Disease Provide a Better Understanding of Nodular Glomerulosclerosis.
Herrera GA; Turbat-Herrera EA; Teng J
Nephron; 2016; 132(2):119-36. PubMed ID: 26794829
[TBL] [Abstract][Full Text] [Related]
2. An in vitro model of light chain deposition disease.
Keeling J; Herrera GA
Kidney Int; 2009 Mar; 75(6):634-45. PubMed ID: 18923384
[TBL] [Abstract][Full Text] [Related]
3. Glomerulopathic light chain-mesangial cell interactions modulate in vitro extracellular matrix remodeling and reproduce mesangiopathic findings documented in vivo.
Herrera GA; Russell WJ; Isaac J; Turbat-Herrera EA; Tagouri YM; Sanders PW; Picken MM; Dempsey S
Ultrastruct Pathol; 1999; 23(2):107-26. PubMed ID: 10369104
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic plasticity of mesenchymal stem cells is crucial for mesangial repair in a model of immunoglobulin light chain-associated mesangial damage.
Herrera GA; Teng J; Zeng C; Xu H; Liang M; Alexander JS; Liu B; Boyer C; Turbat-Herrera EA
Ultrastruct Pathol; 2018; 42(3):262-288. PubMed ID: 29668344
[TBL] [Abstract][Full Text] [Related]
5. Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns.
Teng J; Russell WJ; Gu X; Cardelli J; Jones ML; Herrera GA
Lab Invest; 2004 Apr; 84(4):440-51. PubMed ID: 14990980
[TBL] [Abstract][Full Text] [Related]
6. Healing the damaged mesangium in nodular glomerulosclerosis using mesenchymal stem cells (MSCs): Expectations and challenges.
Herrera GA; Zeng C; Turbat-Herrera EA; Teng J
Ultrastruct Pathol; 2016; 40(2):61-70. PubMed ID: 27031175
[TBL] [Abstract][Full Text] [Related]
7. Integrated expression of glomerular extracellular matrix proteins and beta 1 integrins in monoclonal light chain-related renal diseases.
Turbat-Herrera EA; Isaac J; Sanders PW; Truong LD; Herrera GA
Mod Pathol; 1997 May; 10(5):485-95. PubMed ID: 9160315
[TBL] [Abstract][Full Text] [Related]
8. Response of mesangial cells to low-density lipoprotein and angiotensin II in diabetic (OLETF) rats.
Okada M; Takemura T; Yanagida H; Yoshioka K
Kidney Int; 2002 Jan; 61(1):113-24. PubMed ID: 11786091
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of glomerulosclerosis in light chain deposition disease. Role for transforming growth factor-beta.
Zhu L; Herrera GA; Murphy-Ullrich JE; Huang ZQ; Sanders PW
Am J Pathol; 1995 Aug; 147(2):375-85. PubMed ID: 7639331
[TBL] [Abstract][Full Text] [Related]
10. AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells.
Keeling J; Teng J; Herrera GA
Lab Invest; 2004 Oct; 84(10):1322-38. PubMed ID: 15286662
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin light-chain toxicity in a mouse model of monoclonal immunoglobulin light-chain deposition disease.
Bender S; Ayala MV; Bonaud A; Javaugue V; Carrion C; Oblet C; Rinsant A; Kaaki S; Oruc Z; Boyer F; Paquet A; Pons N; Hervé B; Ashi MO; Jaccard A; Delpy L; Touchard G; Cogné M; Bridoux F; Sirac C
Blood; 2020 Oct; 136(14):1645-1656. PubMed ID: 32559766
[TBL] [Abstract][Full Text] [Related]
12. Understanding Mesangial Pathobiology in AL-Amyloidosis and Monoclonal Ig Light Chain Deposition Disease.
Herrera GA; Teng J; Turbat-Herrera EA; Zeng C; Del Pozo-Yauner L
Kidney Int Rep; 2020 Nov; 5(11):1870-1893. PubMed ID: 33163710
[TBL] [Abstract][Full Text] [Related]
13. Morphologic heterogeneity of renal light-chain deposition disease.
Gokden N; Barlogie B; Liapis H
Ultrastruct Pathol; 2008; 32(1):17-24. PubMed ID: 18300034
[TBL] [Abstract][Full Text] [Related]
14. The current clinical problems for early phase of diabetic nephropathy and approach for pathogenesis of diabetic nephropathy.
Doi T; Mima A; Matsubara T; Tominaga T; Arai H; Abe H
Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S21-4. PubMed ID: 18842318
[TBL] [Abstract][Full Text] [Related]
15. Three-dimensional architecture of glomerular extracellular matrices in diabetic glomerulosclerosis.
Makino H; Nishimura S; Haramoto T; Yamasaki Y; Ikeda S; Ota Z
J Diabet Complications; 1991; 5(2-3):124-5. PubMed ID: 1770017
[TBL] [Abstract][Full Text] [Related]
16. The distribution and regulation of integrin-linked kinase in normal and diabetic kidneys.
Guo L; Sanders PW; Woods A; Wu C
Am J Pathol; 2001 Nov; 159(5):1735-42. PubMed ID: 11696434
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal light chain--mesangial cell interactions: early signaling events and subsequent pathologic effects.
Russell WJ; Cardelli J; Harris E; Baier RJ; Herrera GA
Lab Invest; 2001 May; 81(5):689-703. PubMed ID: 11351041
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinases and mesangial remodeling in light chain-related glomerular damage.
Keeling J; Herrera GA
Kidney Int; 2005 Oct; 68(4):1590-603. PubMed ID: 16164636
[TBL] [Abstract][Full Text] [Related]
19. Light chain deposition nephropathy in necropsy material.
Iványi B; Varga G; Nagy J; Berkessy S; Keresztury S
Zentralbl Pathol; 1991; 137(4):366-71. PubMed ID: 1768689
[TBL] [Abstract][Full Text] [Related]
20. Tetrahydrobiopterin contributes to the proliferation of mesangial cells and accumulation of extracellular matrix in early-stage diabetic nephropathy.
Wang J; Yang Q; Nie Y; Guo H; Zhang F; Zhou X; Yin X
J Pharm Pharmacol; 2017 Feb; 69(2):182-190. PubMed ID: 28033650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
